Literature DB >> 11386605

Plasma glucose reference interval in a low-risk population. 2. Impact of the new WHO and ADA recommendations on the diagnosis of diabetes mellitus.

L G Jørgensen1, M Stahl, I Brandslund, P Hyltoft Petersen, K Borch-Johnsen, N de Fine Olivarius.   

Abstract

The aim of the study was to establish a reference interval of fasting venous plasma glucose (FPG) from healthy individuals. A prospective modified cross-sectional population-based study was made with random selection of 2100 persons in age-stratified groups > or = 18 years identified from the local Personal Identification Register. The invitation was accepted by 755 persons, of which 726 aged 18-92 years were eligible. They did not have a diabetes diagnosis, were non-pregnant and capable of fasting for 8 h. All participants filled in a questionnaire on medical risk factors. Blood for the FPG and haemoglobin Alc (HbAlc) measurements was drawn in accordance with a standardized procedure. A total of 302 participants carried diabetes risk indicators and were ruled out. The FPG concentrations in the remaining low-risk population (n=424) was ln Gaussian distributed. The FPG 97.50 centile in this group was 6.4 mmol/L (95% CI: 6.3-6.5 mmol/L), in contrast to the WHO and ADA theoretical limit of 6.1 mmol/L. Their diagnostic decision limit of 7.0 mmol/L FPG corresponded to the 99.86 centile of the FPG reference distribution (95% CI: 6.8-7.1). Subclassification of the reference population showed increasing FPG with increasing BMI and age and was higher in men than in women. The study determined the FPG 95% interfractile reference interval in a healthy population. The interval in glucose concentration between the 97.5 centile of the reference interval and the ADA-WHO diagnostic limit is very narrow. The clinical application of the diagnostic discriminator and the interpretation of the WHO-ADA grey zone from 6.1 to 7.0 mmol/L FPG may consequently be biased because of poorly defined limits and influence from BMI, age and gender.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11386605     DOI: 10.1080/003655101300133621

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  3 in total

Review 1.  The impact of new guidelines for glucose tolerance testing on clinical practice and laboratory services.

Authors:  Andrew W Lyon; Erik T Larsen; Alun L Edwards
Journal:  CMAJ       Date:  2004-10-26       Impact factor: 8.262

2.  Making the most of a patient's laboratory data: optimisation of signal-to-noise ratio.

Authors:  Per Hyltoft Petersen
Journal:  Clin Biochem Rev       Date:  2005-11

3.  Glycolysis inhibitors negatively bias blood glucose measurements: potential impact on the reported prevalence of diabetes mellitus.

Authors:  W S Waring; L E Evans; C T Kirkpatrick
Journal:  J Clin Pathol       Date:  2007-07       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.